Q2 2023 · 13F-HR
Athyrium Capital Management, LPholdings as filed
Filed 2023-08-14 · accession 0001123292-23-000094
$154.1M
Reported value
7
Positions
2023-06-30
Period end
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 74319FAB3 | — | Biora Inc. | $60.5M | 39.2% | 103,500,000 | Common | NONE |
| 682143AG7 | OMER 5.25 02/15/26 | Omeros Corp | $52.8M | 34.2% | 71,979,000 | Common | NONE |
| 682143AE2 | — | Omeros Corp | $11.0M | 7.16% | 11,005,000 | Common | NONE |
| 699374AB0 | — | Paratek Pharmaceuticals Inc. | $8.8M | 5.74% | 9,000,000 | Common | NONE |
| G6S41R101 | RVLPQ | RVL PHARMACEUTICALS PLC | $8.2M | 5.31% | 14,600,444 | Common | SOLE |
| 74319F305 | — | Biora Inc. | $6.5M | 4.23% | 1,694,481 | Common | SOLE |
| 74587V107 | PBYI | PUMA BIOTECHNOLOGY INC | $6.3M | 4.10% | 1,792,114 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.